[
  {
    "ts": null,
    "headline": "Sangamo Therapeutics: Left At The Alter (Rating Downgrade)",
    "summary": "Sangamo Therapeutics faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price and future prospects.",
    "url": "https://finnhub.io/api/news?id=be2968fa59ff4f0ad46016117f9f49457dfbc7ff9a5bb24694ffc8ff32d59c45",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735678801,
      "headline": "Sangamo Therapeutics: Left At The Alter (Rating Downgrade)",
      "id": 132221199,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2033001899/image_2033001899.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Sangamo Therapeutics faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price and future prospects.",
      "url": "https://finnhub.io/api/news?id=be2968fa59ff4f0ad46016117f9f49457dfbc7ff9a5bb24694ffc8ff32d59c45"
    }
  },
  {
    "ts": null,
    "headline": "Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends hemophilia pact",
    "summary": "Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends hemophilia pact",
    "url": "https://finnhub.io/api/news?id=6a878f1c273a5aa5e55ad3a3373cf8fbddaa968dd2307160dbbebea938c2b54b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735670700,
      "headline": "Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends hemophilia pact",
      "id": 132323921,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends hemophilia pact",
      "url": "https://finnhub.io/api/news?id=6a878f1c273a5aa5e55ad3a3373cf8fbddaa968dd2307160dbbebea938c2b54b"
    }
  },
  {
    "ts": null,
    "headline": "Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership",
    "summary": "Sangamo Therapeutics' (SGMO) shares were sinking intraday Tuesday after the company said its partner",
    "url": "https://finnhub.io/api/news?id=902ea8ca9430f0e39a23fd9c0b980de15c95afb4f085a286e0160ba4b6f8706d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735665631,
      "headline": "Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership",
      "id": 132216652,
      "image": "https://media.zenfs.com/en/mt_newswires_premium_news_706/47ad596ec257093a4e743f8d003c79bf",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Sangamo Therapeutics' (SGMO) shares were sinking intraday Tuesday after the company said its partner",
      "url": "https://finnhub.io/api/news?id=902ea8ca9430f0e39a23fd9c0b980de15c95afb4f085a286e0160ba4b6f8706d"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Sangamo Shares Fall After Pfizer Exits Collaboration; Dave Denies DOJ Allegations",
    "summary": "The Dow Jones Industrial Average and the S&P 500 were basically flat, while the Nasdaq Composite was",
    "url": "https://finnhub.io/api/news?id=2adbb31d528f92d59d043524fee5cb71cc7d61651de82013835969d71c8fafec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735663492,
      "headline": "Top Midday Stories: Sangamo Shares Fall After Pfizer Exits Collaboration; Dave Denies DOJ Allegations",
      "id": 132216379,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average and the S&P 500 were basically flat, while the Nasdaq Composite was",
      "url": "https://finnhub.io/api/news?id=2adbb31d528f92d59d043524fee5cb71cc7d61651de82013835969d71c8fafec"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future",
    "summary": "Sangamo faces steep drop after Pfizer ends partnership, raising concerns about its hemophilia therapy's future",
    "url": "https://finnhub.io/api/news?id=6934996a045d055bf37163c42a8a9121204000ffafa8c9f8663e193a877bc5a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735661914,
      "headline": "Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future",
      "id": 132216654,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/a6747b57575b9aed257eda286a090ef6",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Sangamo faces steep drop after Pfizer ends partnership, raising concerns about its hemophilia therapy's future",
      "url": "https://finnhub.io/api/news?id=6934996a045d055bf37163c42a8a9121204000ffafa8c9f8663e193a877bc5a4"
    }
  },
  {
    "ts": null,
    "headline": "Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact",
    "summary": "Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.",
    "url": "https://finnhub.io/api/news?id=f6d1f59b8d8d2972068f5f92cfeae0495634a486d997393bcb438c7fcb51c949",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735659297,
      "headline": "Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact",
      "id": 132216655,
      "image": "https://www.investopedia.com/thmb/x-GSKY2UqGRSgYGdG5PxfQtdQas=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2160341146-28d87111c7d94ca8818358fbbce48184.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.",
      "url": "https://finnhub.io/api/news?id=f6d1f59b8d8d2972068f5f92cfeae0495634a486d997393bcb438c7fcb51c949"
    }
  },
  {
    "ts": null,
    "headline": "SGMO Pre-Market Shares Drop 40% Over Pfizer (PFE) Deal Collapse",
    "summary": "Investors continued to sell off shares in Sangamo Therapeutics Inc. (NASDAQ:SGMO) before market open on Tuesday following announcements that pharmaceutical giant Pfizer Inc. (NYSE:PFE) terminated their hemophilia A gene therapy co-development agreement. As of 8:53 am on Tuesday, shares of the company declined anew by 50.85 percent to $1.08 each. The previous day’s trading also […]",
    "url": "https://finnhub.io/api/news?id=0232e5f2c753c44babbaabc675d854119b37a3a7d957f6e337c570d85b4e766f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735658608,
      "headline": "SGMO Pre-Market Shares Drop 40% Over Pfizer (PFE) Deal Collapse",
      "id": 132216656,
      "image": "https://media.zenfs.com/en/insidermonkey.com/c9536d029b977f0e02e93257880d827c",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investors continued to sell off shares in Sangamo Therapeutics Inc. (NASDAQ:SGMO) before market open on Tuesday following announcements that pharmaceutical giant Pfizer Inc. (NYSE:PFE) terminated their hemophilia A gene therapy co-development agreement. As of 8:53 am on Tuesday, shares of the company declined anew by 50.85 percent to $1.08 each. The previous day’s trading also […]",
      "url": "https://finnhub.io/api/news?id=0232e5f2c753c44babbaabc675d854119b37a3a7d957f6e337c570d85b4e766f"
    }
  },
  {
    "ts": null,
    "headline": "Sangamo Therapeutics Stock Plummets 50% After Pfizer Ends Hemophilia Treatment Partnership",
    "summary": "The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator.",
    "url": "https://finnhub.io/api/news?id=385fd641e36ac0103cbe2b60e7d4155149a791704dd1524533d082b51381dc52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735658340,
      "headline": "Sangamo Therapeutics Stock Plummets 50% After Pfizer Ends Hemophilia Treatment Partnership",
      "id": 132216657,
      "image": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator.",
      "url": "https://finnhub.io/api/news?id=385fd641e36ac0103cbe2b60e7d4155149a791704dd1524533d082b51381dc52"
    }
  },
  {
    "ts": null,
    "headline": "Sangamo stock plummets 50% after Pfizer ends gene therapy deal",
    "summary": "Sangamo Therapeutics Inc. (SGMO) shares plunged in Tuesday's pre-market trading by over 50% after Pfizer Inc. (PFE) terminated its partnership with the company. The two were collaborating on a gene therapy program to co-develop a treatment for hemophilia A. Sangamo is exploring \"all options\" to continue the program. Morning Brief co-hosts Madison Mills and Seana Smith break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Angel Smith",
    "url": "https://finnhub.io/api/news?id=353c60e19fe6de6be66730b53e340de7bb731d14946a5425aed13173dc99530c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735657005,
      "headline": "Sangamo stock plummets 50% after Pfizer ends gene therapy deal",
      "id": 132216658,
      "image": "https://s.yimg.com/ny/api/res/1.2/86IrPftpFSavXqrp_b57PQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/64ca0570-c77f-11ef-bfdb-2dac870d0333",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Sangamo Therapeutics Inc. (SGMO) shares plunged in Tuesday's pre-market trading by over 50% after Pfizer Inc. (PFE) terminated its partnership with the company. The two were collaborating on a gene therapy program to co-develop a treatment for hemophilia A. Sangamo is exploring \"all options\" to continue the program. Morning Brief co-hosts Madison Mills and Seana Smith break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Angel Smith",
      "url": "https://finnhub.io/api/news?id=353c60e19fe6de6be66730b53e340de7bb731d14946a5425aed13173dc99530c"
    }
  },
  {
    "ts": null,
    "headline": "Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact",
    "summary": "On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc (NYSE:PFE). Pfizer decided to terminate the global collaboration and license agreement between the parties. Sangamo intends to explore all options to advance the program, including seeking a potential new colla",
    "url": "https://finnhub.io/api/news?id=6e683217334121d9a6ae8b769baf50c742caa07c0df86f3cdcd3a0b9d84b8e24",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735654459,
      "headline": "Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact",
      "id": 132216659,
      "image": "https://media.zenfs.com/en/Benzinga/596495aead51bbf7f06abd7d97beb0c1",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc (NYSE:PFE). Pfizer decided to terminate the global collaboration and license agreement between the parties. Sangamo intends to explore all options to advance the program, including seeking a potential new colla",
      "url": "https://finnhub.io/api/news?id=6e683217334121d9a6ae8b769baf50c742caa07c0df86f3cdcd3a0b9d84b8e24"
    }
  },
  {
    "ts": null,
    "headline": "Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership",
    "summary": "Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.",
    "url": "https://finnhub.io/api/news?id=4f00b6e5471706aa5acc5d9d17808167266ac8ce50f3fe906275436fdb00fb6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735651844,
      "headline": "Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership",
      "id": 132214213,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/GettyImages-1170350235-e1735646891414.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.",
      "url": "https://finnhub.io/api/news?id=4f00b6e5471706aa5acc5d9d17808167266ac8ce50f3fe906275436fdb00fb6d"
    }
  },
  {
    "ts": null,
    "headline": "NIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan Stanley",
    "summary": "Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the National Institutes of Health and University of Pennsylvania regarding past and future royalties on the company and partner Pfizer’s (PFE) COVID vaccine, Comirnaty. Noting that the deal will result in two low-single digit percentage royalties on forward sales of Comirnaty and the companies will pay $1.15B for historical royalties, the firm says it views this as",
    "url": "https://finnhub.io/api/news?id=38328316cd4ae32966dc1c5173078cc159f7472c972ee3208d37792ed523abd1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735651811,
      "headline": "NIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan Stanley",
      "id": 132214406,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the National Institutes of Health and University of Pennsylvania regarding past and future royalties on the company and partner Pfizer’s (PFE) COVID vaccine, Comirnaty. Noting that the deal will result in two low-single digit percentage royalties on forward sales of Comirnaty and the companies will pay $1.15B for historical royalties, the firm says it views this as",
      "url": "https://finnhub.io/api/news?id=38328316cd4ae32966dc1c5173078cc159f7472c972ee3208d37792ed523abd1"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons to Buy Pfizer Stock Like There's No Tomorrow",
    "summary": "The beaten-down pharmaceutical giant could double your investment over three to four years.",
    "url": "https://finnhub.io/api/news?id=45aa9c0b1c3e28360bc156770e78f9167081fce613d1ffbdcc1d076039e0824d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735648200,
      "headline": "3 Reasons to Buy Pfizer Stock Like There's No Tomorrow",
      "id": 132213397,
      "image": "https://g.foolcdn.com/editorial/images/802306/pfizer_logo_on_glass_pfe-2.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The beaten-down pharmaceutical giant could double your investment over three to four years.",
      "url": "https://finnhub.io/api/news?id=45aa9c0b1c3e28360bc156770e78f9167081fce613d1ffbdcc1d076039e0824d"
    }
  },
  {
    "ts": null,
    "headline": "Drugmakers to raise US prices on over 250 medicines starting Jan. 1",
    "summary": "Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol Myers Squibb's cancer cell therapies and vaccines from France's Sanofi at the start of 2025, according to data analyzed by healthcare research firm 3 Axis Advisors.  Nearly all of the drug price increases are below 10% - most well below.  The median price increase of the drugs being hiked Jan. 1 is 4.5%, which is in line with the median for all price increases last year.",
    "url": "https://finnhub.io/api/news?id=d97458f7e35f83062b260250e78aaf2d37cae691e9c4b750de7da00b97e0dee3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735646729,
      "headline": "Drugmakers to raise US prices on over 250 medicines starting Jan. 1",
      "id": 132213399,
      "image": "https://media.zenfs.com/en/reuters-finance.com/dc39e4db2d75efd46592cb6714eeacc3",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol Myers Squibb's cancer cell therapies and vaccines from France's Sanofi at the start of 2025, according to data analyzed by healthcare research firm 3 Axis Advisors.  Nearly all of the drug price increases are below 10% - most well below.  The median price increase of the drugs being hiked Jan. 1 is 4.5%, which is in line with the median for all price increases last year.",
      "url": "https://finnhub.io/api/news?id=d97458f7e35f83062b260250e78aaf2d37cae691e9c4b750de7da00b97e0dee3"
    }
  },
  {
    "ts": null,
    "headline": "Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal",
    "summary": "Investing.com -- Sangamo Therapeutics Inc (NASDAQ:SGMO) announced on Monday that Pfizer (NYSE:PFE) has ended their partnership to co-develop a gene therapy for hemophilia A (HemoA), sending Sangamo’s shares crashing 50% in premarket trading Tuesday.",
    "url": "https://finnhub.io/api/news?id=60b10cd911ba9a6653a67e2a2c47aac8587b3b2d6a3e0aa23061745d1797ffa7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735645080,
      "headline": "Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal",
      "id": 132213105,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investing.com -- Sangamo Therapeutics Inc (NASDAQ:SGMO) announced on Monday that Pfizer (NYSE:PFE) has ended their partnership to co-develop a gene therapy for hemophilia A (HemoA), sending Sangamo’s shares crashing 50% in premarket trading Tuesday.",
      "url": "https://finnhub.io/api/news?id=60b10cd911ba9a6653a67e2a2c47aac8587b3b2d6a3e0aa23061745d1797ffa7"
    }
  },
  {
    "ts": null,
    "headline": "SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate",
    "summary": "Sangamo stock crashes 60.4% as partner Pfizer decides to end collaboration for hemophilia A candidate, giroctocogene fitelparvovec.",
    "url": "https://finnhub.io/api/news?id=712daa31ebc518bbee1477e4d8e32d724c7a96201ada953b29345360b7317bda",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735642500,
      "headline": "SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate",
      "id": 132214218,
      "image": "https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Sangamo stock crashes 60.4% as partner Pfizer decides to end collaboration for hemophilia A candidate, giroctocogene fitelparvovec.",
      "url": "https://finnhub.io/api/news?id=712daa31ebc518bbee1477e4d8e32d724c7a96201ada953b29345360b7317bda"
    }
  }
]